泽璟制药注射用ZG006与依托泊苷及顺铂联用临床试验获批

Core Viewpoint - ZaiJing Pharmaceutical has received approval from the National Medical Products Administration for clinical trials of its drug ZG006 in combination with Etoposide and Cisplatin for advanced neuroendocrine cancer [1] Group 1: Company Developments - ZG006 is a trispecific antibody drug developed through the company's dual/multi-specific antibody research platform [1] - The drug has received clinical trial approval from both the US FDA and China's NMPA, and has been included in the breakthrough therapy category by the National Medical Products Administration [1] - ZG006 has also been granted orphan drug designation by the US FDA [1]